Monitoring of systemic inflammatory response in diabetic patients with deep foot infection treated with negative pressure wound therapy.
BACKGROUND
The purpose of this study was to establish the safety of negative pressure wound therapy (NPWT) in the treatment of acutely debrided, deep diabetic foot infections (DDFI) and to determine the value of inflammatory markers in monitoring of treatment of these infections with negative pressure wound therapy.


METHODS
A group of ten patients with DDFI treated by radical surgical debridement and simultaneous NPWT was prospectively studied. During the debridement, a deep tissue sample was obtained and sent for microbiological testing. The patients were followed clinically for 10 days and NPWT dressings were changed every 2 to 3 days or sooner when indicated. The peripheral blood samples were obtained before the radical debridement and 3 and 10 days afterwards and concentrations of white blood cell, neutrophils, lymphocytes and C-reactive protein (CRP) were measured. The changes in concentration of inflammatory markers were analyzed with a Friedman test.


RESULTS
In all but one patient the presence of DDFI was confirmed by the culture results. At baseline, the elevated WBC and neutrophil concentrations were observed only in half of the patients while the CRP concentration was elevated in nine patients. During followup, all patients showed a favorable clinical evolution and statistically significant decrease of WBC, neutrophils and CRP (p<0.001). There were not statistically significant changes in lymphocyte count.


CONCLUSIONS
NPWT can be safely applied in acutely debrided DDFI. CRP seems to be the most adequate parameter for both diagnosis and monitoring of treatment of DDFI.
Department of General and Vascular Surgery, Poznań University of Medical Sciences, Poznań, Poland.
Łukasz
Ł
Dzieciuchowicz
Łukasz
Ł
Kruszyna
Zbigniew
Z
Krasiński
Gaudencio
G
Espinosa
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D003646:Debridement; D017719:Diabetic Foot / Q000145:classification / Q000473:pathology / Q000628:therapy*; D005260:Female; D005734:Gangrene / Q000145:classification / Q000628:therapy; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D054843:Negative-Pressure Wound Therapy; D009504:Neutrophils / Q000378:metabolism; D010019:Osteomyelitis / Q000145:classification / Q000175:diagnosis / Q000382:microbiology / Q000628:therapy*; D011446:Prospective Studies; D012680:Sensitivity and Specificity
D000900:Anti-Bacterial Agents; D015415:Biomarkers; D002097:C-Reactive Protein